Coherus BioSciences, Inc. (CHRS)

Market Cap	659.56M
Revenue (ttm)	239.06M
Net Income (ttm)	-278.61M
Shares Out	77.78M
EPS (ttm)	-3.59
PE Ratio	n/a
Forward PE	32.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	83,775
Open	8.45
Previous Close	8.48
Day's Range	8.34 - 8.55
52-Week Range	5.58 - 14.11
Beta	0.87
Analysts	Buy
Price Target	18.11 (+113.31%)
Earnings Date	Feb 16, 2023

About CHRS

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab bios...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2014
• Employees: 376
• Stock Exchange: NASDAQ
• Ticker Symbol: CHRS

Analyst Forecast

According to 14 analysts, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is $18.11, which is an increase of 113.31% from the latest price.

Price Target

$18.11

(113.31% upside)

Analyst Consensus: Buy